Clinical Trial: STOP-HER2: Stopping Trastuzumab in HER2+ MBC
Study Status: Completed
Recruit Status: RECRUITING
Condition: Breast Cancer
Study Type: INTERVENTIONAL
Official Title: The STOP-HER2 Trial: A Phase 2 Study of Stopping Trastuzumab - Outcomes in Patients With HER2+ Metastatic Breast Cancer
Brief Summary:
This study is being done to see if anti-HER2 treatment be safely stopped in patients with HER2-positive metastatic breast cancer (MBC) that have had exceptional response to treatment.Exceptional response" is considered as cancer progression being controlled for three years or more since starting anti-HER2 treatment.
Read more